Exploring the potential of AgNPs in modulating the PI۳K/AKT/mTOR pathway via miR-۱۳۳a regulation in MCF-۷ breast cancer cells

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 195

فایل این مقاله در 11 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_NAMJ-11-1_005

تاریخ نمایه سازی: 25 آذر 1402

چکیده مقاله:

Objective(s): Breast cancer is the most common malignancy in women. MiRNAs modulate the PI۳K/AKT/mTOR (PAM) pathway, functioning as either tumor suppressors or oncogenes. This research explores the impact of AgNPs on breast cancer cells while emphasizing the interplay between miR-۱۳۳a and the PAM pathway and uncovering regulatory mechanisms.Materials and Methods: To assess the impact of AgNPs on cell growth and survival, we performed an MTT assay. Additionally, we employed bioinformatic methodologies to predict potential targets of miR-۱۳۳a within the PAM pathway. We quantified the expression levels of miR-۱۳۳a, PI۳K, AKT, PTEN, and mTOR in MCF-۷ cells after exposure to AgNPs using qRT-PCR. Furthermore, we employed Western blotting to evaluate the protein expression of mTOR.Results: The MTT assay results demonstrated a significant dose- and time-dependent inhibition of breast cancer cells by AgNPs. The qRT-PCR analysis revealed an upregulation in the mRNA expression levels of PI۳K and AKT, accompanied by a downregulation in the mRNA expression levels of PTEN and mTOR upon exposure to AgNPs. However, the efficacy and expression level of miR-۱۳۳a as a tumor suppressor in breast cancer cells remained unchanged following exposure to AgNPs (IC۵۰).Conclusion: The study found that AgNPs inhibit breast cancer cell growth, affecting the PAM pathway, but miR-۱۳۳a remained unchanged, suggesting AgNPs may not primarily act through miR-۱۳۳a. Further research is needed, but caution is advised when using AgNPs for cancer control and treatment.

نویسندگان

Mohammadjavad Hossein Tehrani

Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Nasrin Ziamajidi

Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Roghayeh Abbasalipourkabir

Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Zeinab Barartabar

Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Somayeh Aslani

Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, ...
  • Taká P, Michalková R, Martina Č, Bedlovi Z, Balážová Ľ, ...
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. ...
  • Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, ...
  • Hua YT, Xu WX, Li H, Xia M. Emerging roles ...
  • Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, ...
  • Rakowski M, Porębski S, Grzelak A. Silver nanoparticles modulate the ...
  • Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol ...
  • Yuan TL, Cantley LC. PI۳K pathway alterations in cancer: variations ...
  • Nguyen K-TT, Tajmir P, Lin CH, Liadis N, Zhu X-D, ...
  • Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. ...
  • Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, ...
  • نمایش کامل مراجع